IRB #H-29665/ Prostate CK: Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost To The Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer

CIRB #H-37226/ NRG #GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Central IRB #pend/ Exelixis #XL184-315: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer (not yet submitted to IRB)